Joint safety and neurologic events with subcutaneous tanezumab or oral nonsteroidal anti-inflammatory drugs in subgroups of patients with osteoarthritis from an 80-week phase 3 study. (April 2021) - Hunter, D.J.; Radominski, S.; Rodriguez Ulloa, S.; Goranov, I.; Radunovic, G.; Chang, C.; Pixton, G.; Hickman, A.; Fountaine, R.J.; Brown, M.T.; Viktrup, L.; West, C.